Towards Healthcare
Cell Viability Assays Market Surging to USD 2.05 Billion by 2025

Cell Viability Assays Market 2025 North America Leads with 40% Share, APAC to Grow Fastest

Market insights predict, the cell viability assays industry is expected to grow from USD 1.89 billion in 2024 to USD 4.24 billion by 2034, driven by a CAGR of 8.54%. The growing research and development activities and stringent regulatory policies drive the market. The availability of state-of-the-art research and development facilities and favorable government support contribute to North America’s dominance.

Content

  • Insight Code: 5859
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The cell viability assays market is projected to reach USD 4.24 billion by 2034, growing at a CAGR of 8.54% from 2025 to 2034.

North America is leading the cell viability assays market due to the availability of state-of-the-art research and development facilities, favorable government support, and the presence of key players.

The cell viability assays market includes 6 segments including by product type, by assay type, by application, by end-use, by technology, and by region.

Some key players include Thermo Fisher Scientific, Promega Corporation, and Sartorius AG.

Key trends include the growing research and development activities, the rising prevalence of chronic disorders, and the increasing demand for personalized medicines.

MTS, resazurin, TMRE, calcein violet, and ATP luminescence are different types of cell viability assays.

World Health Organization, National Institute of Health, Government of Canada, duetschland.de
Any Questions